Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC - European Medical Journal

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses phase 3 clinical trials of atezolizumab, an anti-PD-L1 monoclonal antibody, compared with standard chemotherapy in PD-L1-selected chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC).

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>